Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: A randomized controlled trial

JAMA

Volumn 304, Issue 1, 2010, Pages 45-52

  Wilkens, Philip ^a,c   Scheel, Inger B ^b   Grundnes, Oliver ^a,d   Hellum, Christian ^a   Storheim, Kjersti ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SINTEF   (Norway)

^c Norwegian Research Center for Active Rehabilitation (NAR)   (Norway)

^d Hjelp24NIMI   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954367186     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.893     Document Type: Article

References (40)

1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the twoin combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808.
2. Borenstein D. Does osteoarthritis of the lumbar spine cause chronic low back pain? Curr Pain Headache Rep. 2004;8(6):512-517.
3. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344(5):363-370.
4. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2009;30(3):357-363.
5. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283(11):1469-1475. (Pubitemid 30151826)
6. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensivemeta-analysis. Arch Intern Med. 2003;163(13):1514-1522. (Pubitemid 36835094)
7. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946.
8. Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001;(1):CD002946.
9. Hopman WM, Towheed TE, Gao Y, et al. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage. 2006;14(12):1288- 1293. (Pubitemid 44774444)
10. Herrero-Beaumont G, Román JA, Trabado MC, et al. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs placebo and acetaminophen: results from the Glucosamine Unum In Die Efficacy (GUIDE) trial [abstract]. Arthritis Rheum. 2005;9(suppl):1203. doi:10.1016/S1063-4584(05)80353-X.
11. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555-567.
12. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11(4):290-298. (Pubitemid 36410882)
13. Igarashi A, Kikuchi S, Konno S. Correlation between inflammatory cytokines released from the lumbar facet joint tissue and symptoms in degenerative lumbar spinal disorders. J Orthop Sci. 2007;12(2):154-160. (Pubitemid 46723682)
14. Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans. 2007;35(Pt 4):652-655. (Pubitemid 47310333)
15. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther. 1980;3(4):260-272. (Pubitemid 11122261)
16. Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebocontrolled pilot study. Mil Med. 1999;164(2):85-91.
17. Tant L, Gillard B, Appelboom T.Open-label, randomized, controlled pilot study of the effects of a glucosamine complex on low back pain. Current Therapeutic Res. 2005;66(6):511-521 doi:10.1016/j.curtheres.2005.12.009.
18. Grundnes O; Ullevaal University Hospital. The glucosamine-study: the effect of glucosamine in treatment of chronic low back pain (clinicaltrials.gov identifier, NCT 00404079). http://clinicaltrials.gov/ct2/results?term= NCT+00404079. Accessed May 11, 2009.
19. European Journalism Centre. Media landscape - Norway. http://www.ejc.net/media-landscape/article/norway/. Accessed June 10, 2010.
20. van Tulder M, Becker A, Bekkering T, et al. Chapter 3: European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006;15(suppl 2):s169-s191.
21. Luoma K, Riihimaki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminen A. Low back pain in relation to lumbar disc degeneration. Spine. 2000; 25(4):487-492. (Pubitemid 30115569)
22. Pathria M, Sartoris DJ, Resnick D. Osteoarthritis of the facet joints: accuracy of oblique radiographic assessment. Radiology. 1987;164(1):227-230. (Pubitemid 17089909)
23. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. Radiology. 1988;166(1 pt 1):193-199.
24. Aprill C, Bogduk N. High-intensity zone: a diagnostic sign of painful lumbar disc on magnetic resonance imaging. Br J Radiol. 1992;65(773):361-369.
25. Grotle M, Brox JI, Vollestad NK. Cross-cultural adaptation of the Norwegian versions of the Roland- Morris Disability Questionnaire and the Oswestry Disability Index. J Rehabil Med. 2003;35(5):241-247. (Pubitemid 37265112)
26. Roland M, Morris R. A study of the natural history of back pain: part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1983;8(2):141-144. (Pubitemid 13089565)
27. Stratford PW, Binkley J, Solomon P, Finch E, Gill C, Moreland J. Defining theminimum level of detectable change for the Roland-Morris questionnaire. Phys Ther. 1996;76(4):359-365. (Pubitemid 126501431)
28. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158. (Pubitemid 33016608)
29. Solberg TK, Olsen JA, Ingebrigtsen T, Hofoss D, Nygaard OP. Health-related quality of life assessment by the EuroQol-5D can provide cost-utility data in the field of low-back surgery. Eur Spine J. 2005;14(10):1000-1007. (Pubitemid 41798052)
30. Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005;19(4):593-607. (Pubitemid 40790489)
31. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19(1):1-15.
32. Waddell G, Newton M, Henderson I, Somerville D, Main CJA. Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain. 1993;52(2):157-168.
33. Pavelká K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-2123.
34. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites the GARP study. Osteoarthritis Cartilage. 2007;15(4):379-385.
35. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268-277.
36. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56(7):2267-2277.
37. Thornton A, Lee P. Publication bias in metaanalysis: its causes and consequences. J Clin Epidemiol. 2000;53(2):207-216. (Pubitemid 30151226)
38. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
39. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064-1069. (Pubitemid 30162810)
40. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13(12):1041-1049. (Pubitemid 41672501)